Colorectal Cancer Clinical Trials

**Epidemiologic/Correlative**

- **UCI 14-25**  
  Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

- **UCI 16-01**  
  Pathway Analysis for Individualized Network Therapeutic for Cancer (PAINT) (Nelson)

- **UCI 16-43**  
  Prospective Collection of Human Colon Cancer Tissue Samples for Development of Patient Derived Xenograft Mouse Models and 3D-Vascularized Microtumor Chambers (Lyou)

- **UCI 17-76**  
  Variations in Local Microbiome Populations in Normal Colorectal Tissue and Polyps (Whiteson)

**Therapeutic - Multi-site (including colon)**

- **UCI 15-74**  
  Phase II Entrectinib Tx Patients with Locally Advanced / Metastatic Solid Tumors Harbor NTRK1/2/3, ROS1, ALK Gene (Ou)

- **UCI 16-96**  
  Phase I Study of the Highly-Selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

- **UCI 17-50**  
  A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate in Subjects with Advanced Solid Tumor (Ou)

- **SWOG S1609**  
  DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Boda)

**Screening**

- **UCI 12-40**  
  Atlas Colorectal Health Network (Park)

- **UCI 14-30**  
  Low Residue Diet vs. Clear Liquid Diet w/ Split dose PEG-ELS for Colon Cleansing Prior to Colonoscopy (Samarasena)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**opening soon**
Colorectal Cancer Therapeutic Clinical Trials

Stage IIA/IIIA (T2N1, T3N0, T3N1)

**Neoadjuvant**

SWOG N1048 Phase II/III Trial of Neoadjuvant FOLFOX w/ Selective Use of Combined Modality Chemoradiation VS Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal CA Pts Undergoing LAR W/Total Mesorectal Excision (Pigazzi)

Stage 0-III

**Post-Adjuvant**

SWOG S0820 Phase IIA Randomized Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High-Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer (Zell)

Stage IV

**1st Line**

UCI 15-96 A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (Zell)

**2nd Line**

ECOG-EAY131 Molecular Analysis for Therapy Choice (MATCH) (Bota)

SWOG S1613** A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in HER2 Amplified Irinotecan-Refractory Metastatic Colorectal Cancer (mCRC) (Dayyani)

UCI 17-28** Immediate Adjuvant Chemotherapy for Invasive Colonic Adenocarcinoma (Pigazzi)

**opening soon**

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu